Abstract
Recent reports have shown that excellent survival outcomes can be achieved in adult Burkitt’s lymphoma with the use of DA-EPOCH-R regimen. When compared to earlier intense pediatric-type protocols, this regimen is less toxic. There are limited reports available on the use of this regimen outside the context of clinical trials. We analyzed the outcomes of patients who were treated with the DA-EPOCH-R regimen [Burkitt’s lymphoma (BL), primary mediastinal B cell lymphoma (PMBCL) and HIV-positive patients with diffuse large B cell lymphoma (DLBCL)] at our center over a 3 year period. Baseline characters, responses, and toxicity data was captured from records. Event-free survival (EFS—from therapy initiation till occurrence of event (non-achievement of complete response or relapse) and overall survival (OS—from therapy initiation till death due to any cause) were estimated using Kaplan–Meier method. Among 41 patients [median age 40 years (18–76)], the following diagnoses were included-HIV negative patients (N = 29): BL (N = 24), PMBCL (N = 5); HIV positive patients (N = 12): BL (N = 8), and DLBCL (N = 4). Among those with BL, majority had stage III/IV disease (N = 21/32, 65%). At the completion of planned therapy, 33 had achieved CR (81%). One patient died due to toxicity. The actuarial EFS and OS at 2 years were 80 and 77% respectively for all patients. The OS at 2 years was 100% for PMBCL, 80% for BL and 50% for HIV-positive DLBCL. Majority of the failures in BL were in patients with advanced disease. DA-EPOCH-R can be used in real-world setting and allows treatment of older patients with BL.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Dunleavy K, Pittaluga S, Shovlin M, Steinberg SM, Cole D, Grant C et al (2013) Low-intensity therapy in adults with Burkitt’s lymphoma. N Engl J Med 369(20):1915–1925
Dunleavy K, Fanale M, LaCasce A, Noy A, Caimi P, Parekh S et al (2014) Preliminary report of a multicenter prospective phase II study of DA-EPOCH-R in MYC-rearranged aggressive B-cell lymphoma. Blood 2014(124):395
Dunleavy K, Pittaluga S, Maeda LS, Advani R, Chen CC, Hessler J et al (2013) Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med 368(15):1408–1416
Thomas DA, Faderl S, O’Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G et al (2006) Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 106(7):1569–1580
Evens AM, Carson KR, Kolesar J, Nabhan C, Helenowski I, Islam N et al (2013) A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt’s lymphoma. Ann Oncol 24(12):3076–3081
Sparano JA, Lee JY, Kaplan LD, Levine AM, Ramos JC, Ambinder RF et al (2010) Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood 115(15):3008–3016
Barta SK, Lee JY, Kaplan LD, Noy A, Sparano JA (2012) Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphoma. Cancer 118(16):3977–3983
Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Müeller SP et al (2014) Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group. J Clin Oncol 32(27):3048–58
Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25(5):579–586
Dunleavy K, Noy A, Abramson JS, LaCasce AS, Link BK, Parekh S et al (2015) Risk-adapted therapy in adults with Burkitt lymphoma: preliminary report of a multicenter prospective phase II study of DA-EPOCH-R. Blood 126:342
Ribera JM, García O, Grande C, Esteve J, Oriol A, Bergua J et al (2013) Dose-intensive chemotherapy including rituximab in Burkitt’s leukemia or lymphoma regardless of human immunodeficiency virus infection status: final results of a phase 2 study (Burkimab). Cancer 119(9):1660–1668
Xicoy B, Ribera JM, Müller M, García O, Hoffmann C, Oriol A et al (2014) Dose-intensive chemotherapy including rituximab is highly effective but toxic in human immunodeficiency virus-infected patients with Burkitt lymphoma/leukemia: parallel study of 81 patients. Leuk Lymphoma 55(10):2341–2348
Hoelzer D, Walewski J, Döhner H, Viardot A, Hiddemann W, Spiekermann K et al (2014) Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial. Blood 124(26):3870–3879
Sengar M, Akhade A, Nair R, Menon H, Shet T, Gujral S et al (2011) A retrospective audit of clinicopathological attributes and treatment outcomes of adolescent and young adult non-Hodgkin lymphomas from a tertiary care center. Indian J Med Paediatr Oncol 32(4):197–203
Acknowledgements
Vanitha N and Rekhadevi for help in collection of data.
Funding
The study was supported by Cancer Institute (WIA) funds. No grant number is applicable. There were no external sources of funding for this project.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
None of the authors have any relevant conflicts of interests to declare.
Rights and permissions
About this article
Cite this article
Ganesan, P., Ganesan, T.S., Atreya, H. et al. DA-EPOCH-R in Aggressive CD 20 Positive B Cell Lymphomas: Real-World Experience. Indian J Hematol Blood Transfus 34, 454–459 (2018). https://doi.org/10.1007/s12288-017-0901-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12288-017-0901-1